NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology firm centered on growing revolutionary therapies for neurodegenerative illnesses and selling wholesome longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna (NASDAQ:), has joined its Scientific Advisory Board. Along with lending his world-class scientific experience to information the corporate’s strategic course, this additionally indicators Dr. Langer’s robust perception within the firm’s mission and potential.
Dr. Langer is a world-renowned scientist, entrepreneur, and biotechnology pioneer. His groundbreaking work in drug supply techniques and tissue engineering has earned him quite a few awards and recognition, together with the celebrated Nationwide Medal of Science and the Charles Stark Draper Prize. As a co-founder of Moderna, Dr. Langer performed a pivotal position in revolutionizing the biotech trade with the event of mRNA-based therapeutics, together with the COVID-19 vaccine. He’s a Professor on the Massachusetts Institute of Expertise (MIT) and a school member of the Harvard“MIT Program in Well being Sciences and Expertise.
Klotho Neurosciences is engaged on the event of novel therapies aimed toward addressing main unmet medical wants in neurodegenerative problems, together with ALS, Alzheimer’s and Parkinson’s illness. The corporate’s platform leverages groundbreaking analysis surrounding the Klotho protein, a robust anti-aging issue that has proven important neuroprotective potential in preclinical fashions. Patents overlaying the corporate’s secreted type of Klotho, s-KL, have been issued within the USA, Europe, Hong Kong and China.
We’re thrilled to welcome Dr. Langer to our Scientific Advisory Board, commented Dr. Joseph Sinkule, the Chairman and CEO of Klotho Neurosciences. His huge expertise in translational drugs, biotechnology, and therapeutic innovation might be invaluable as we advance our pipeline and discover new approaches to treating devastating neurodegenerative illnesses. I might additionally like to notice that I used to be privileged to have labored with Bob Langer some years in the past once I co-authored a scientific paper with him.
Dr. Langer expressing his enthusiasm for becoming a member of Klotho Neurosciences commented, I’m excited to collaborate with the crew at Klotho Neurosciences as they discover the therapeutic potential of the Klotho protein in combating neurodegenerative circumstances. The corporate is engaged on one thing extremely promising, and I am desirous to help their efforts.
As a member of the Scientific Advisory Board, Dr. Langer will present steerage on the scientific and scientific growth of the corporate’s product candidates. Klotho Neurosciences is positioning itself on the forefront of the biotech sector’s efforts to handle probably the most urgent challenges of contemporary drugs, which is the remedy of neurodegenerative illnesses. Dr. Langer’s involvement represents a big milestone for the corporate because it strikes ahead in its mission to develop life-changing therapies for sufferers worldwide primarily based on its patented s-KL expertise platform.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical firm specializing within the growth of patented, novel disease-modifying applied sciences focusing on the mind and central nervous system (CNS) which are seen as key developments in treating neurodegenerative and age-related problems. The Firm obtained unique worldwide rights to platform applied sciences and knowhow to develop innovative protein, gene and cell therapies to deal with age-related pathologies equivalent to ALS, Alzheimer’s and Parkinson’s Illness, a number of sclerosis and uncommon neurodegenerative illnesses. The corporate’s present portfolio consists of its proprietary gene remedy program utilizing DNA and RNA as therapeutics and diagnostics. Different property embrace clinical-stage applications involving antibody biologics focusing on most cancers and autoimmune illnesses, and drug supply by way of a needle-free dry powder jet autoinjector known as Nanoject. The corporate is managed by a crew of people and advisors who’re extremely skilled in biopharmaceutical product growth and commercialization.
For extra info, contact:
Eric Boyd
Investor Relations
E-mail: IR@klothoneuro.com
Web site: www.klothoneuro.com
Ahead-Wanting Statements:
This press launch accommodates forward-looking statements. These statements are made below the protected harbor provisions of the U.S. Personal Securities Litigation Reform Act of 1995. These forward-looking statements typically are recognized by the phrases consider, challenge, anticipate, anticipate, estimate, intend, technique, future, alternative, plan, might, ought to, will, would, might be, will proceed, will possible end result, and comparable expressions. With out limiting the generality of the foregoing, the forward-looking statements on this press launch embrace descriptions of the Firm’s future business operations. Ahead-looking statements are predictions, projections and different statements about future occasions which are primarily based on present expectations and assumptions and, because of this, are topic to dangers and uncertainties. Many elements may trigger precise future occasions to vary materially from the forward-looking statements on this press launch, such because the Firm’s lack of ability to implement its enterprise plans, determine and notice extra alternatives, or meet or exceed its monetary projections and adjustments within the regulatory or aggressive surroundings by which the Firm operates. You must rigorously think about the foregoing elements and the opposite dangers and uncertainties described within the paperwork filed or to be filed by the Firm with the U.S. Securities and Change Fee (the SEC) now and again, which may trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Copies of those paperwork can be found on the SEC’s web site, www.sec.gov. All info supplied herein is as of the date of this press launch, and the Firm undertakes no obligation to replace any forward-looking assertion, besides as required below relevant regulation.
Supply: Klotho Neurosciences, Inc.
